Financial Analyst Summary

Regulatory Query Response

Anlon Healthcare Limited responded to a query from the National Stock Exchange of India (NSE) raised through mail dated December 23, 2025, regarding deficiencies in submission of financial results for the quarter ended June 30, 2025. The exchange had identified two specific issues:

1. Machine Readable Form/Legible copy of Financial Results not submitted

2. Financial results submitted not as per format prescribed by SEBI - Covering letter missing

The company provided the required machine-readable format/legible copy of financial results and attached the covering letter with financial results for the quarter ended June 30, 2025.

Financial Results Details

Balance Sheet Highlights (Standalone, Rs. in Lacs):

  • Total Assets: 19,775.76 (vs. 18,129.99 as of March 31, 2025)
  • Property, Plant and Equipment: 2,241.02 (vs. 2,281.90)
  • Inventories: 5,159.28 (vs. 5,026.31)
  • Trade Receivables: 9,365.71 (vs. 7,499.87)
  • Cash and Cash Equivalents: 185.67 (vs. 144.96)
  • Total Equity: 8,396.86 (vs. 8,042.17)
  • Borrowings (Non-current): 3,841.49 (vs. 3,835.70)
  • Borrowings (Current): 2,000.58 (vs. 1,999.04)

Profitability (Quarter Ended June 30, 2025):

  • Profit for the period: ₹354.69 lakhs

Cash Flow Statement (Rs. in Lacs):

  • Net cash generated by operating activities: 117.88
  • Net cash used in investing activities: (2.80)
  • Net cash used in financing activities: (74.37)
  • Net increase in cash and cash equivalents: 40.71

Company Background

Anlon Healthcare Limited (CIN: U24230GJ2013PLC077543) is a research-intensive manufacturing company engaged in the production of Active Pharmaceutical Ingredients (APIs) and drug intermediates. The company is based in Rajkot, Gujarat, and was listed on both NSE and BSE on September 3, 2025.

Auditor Review

RVD & Co., Chartered Accountants (FRN 143936W) reviewed the financial results and concluded that nothing came to their attention causing them to believe that the statement contains any material misstatement or has not disclosed required information under Regulation 33 of SEBI Listing Regulations.

Topic Tags: Regulatory Response, Financial Results Clarification, Compliance, Quarterly Results, Pharmaceutical Manufacturing